BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McGuffin SA, Pottinger PS, Harnisch JP. Clofazimine in Nontuberculous Mycobacterial Infections: A Growing Niche. Open Forum Infect Dis 2017;4:ofx147. [PMID: 30202770 DOI: 10.1093/ofid/ofx147] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Cameron LH, Peloquin CA, Hiatt P, Mann M, Starke JR, Faircloth J, McNeil JC, Patel A, Ruiz F. Administration and monitoring of clofazimine for NTM infections in children with and without cystic fibrosis. J Cyst Fibros 2021:S1569-1993(21)01351-5. [PMID: 34479810 DOI: 10.1016/j.jcf.2021.08.010] [Reference Citation Analysis]
2 Thapa P, Mohr K, Campbell KK, Saccente M. Sweet Syndrome precipitated by Mycobacterium abscessus in a Laotian Man with Autoantibodies to Interferon Gamma. J Investig Med High Impact Case Rep 2021;9:2324709621990771. [PMID: 33533284 DOI: 10.1177/2324709621990771] [Reference Citation Analysis]
3 Kwak N, Whang J, Yang JS, Kim TS, Kim SA, Yim JJ. Minimal Inhibitory Concentration of Clofazimine Among Clinical Isolates of Nontuberculous Mycobacteria and Its Impact on Treatment Outcome. Chest 2021;159:517-23. [PMID: 32712225 DOI: 10.1016/j.chest.2020.07.040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
4 Valinetz E, Stankiewicz Karita H, Pottinger PS, Jain R. Novel Administration of Clofazimine for the Treatment of Mycobacterium avium Infection. Open Forum Infect Dis 2020;7:ofaa183. [PMID: 32548205 DOI: 10.1093/ofid/ofaa183] [Reference Citation Analysis]
5 Baker AW, Maziarz EK, Lewis SS, Stout JE, Anderson DJ, Smith PK, Schroder JN, Daneshmand MA, Alexander BD, Wallace RJ, Sexton DJ, Wolfe CR. Invasive Mycobacterium abscessus Complex Infection After Cardiac Surgery: Epidemiology, Management, and Clinical Outcomes. Clin Infect Dis 2021;72:1232-40. [PMID: 32133489 DOI: 10.1093/cid/ciaa215] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Anjan S, Morris MI. How can we improve the outcome for transplant patients with nontuberculous mycobacterial infections? Future Microbiol 2018;13:903-14. [PMID: 29888973 DOI: 10.2217/fmb-2018-0006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Egorova A, Jackson M, Gavrilyuk V, Makarov V. Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities. Med Res Rev 2021;41:2350-87. [PMID: 33645845 DOI: 10.1002/med.21798] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Laudone TW, Garner L, Kam CW, Esther CR Jr, McKinzie CJ. Novel therapies for treatment of resistant and refractory nontuberculous mycobacterial infections in patients with cystic fibrosis. Pediatr Pulmonol 2021;56 Suppl 1:S55-68. [PMID: 32609433 DOI: 10.1002/ppul.24939] [Reference Citation Analysis]
9 Quang NT, Jang J. Current Molecular Therapeutic Agents and Drug Candidates for Mycobacterium abscessus. Front Pharmacol 2021;12:724725. [PMID: 34526902 DOI: 10.3389/fphar.2021.724725] [Reference Citation Analysis]
10 Pinapala A, Koh LJ, Ng KH, Tambyah PA, Yap HK. Clofazimine in Mycobacterium abscessus peritonitis: A pediatric case report. Perit Dial Int 2021;41:104-9. [PMID: 32148178 DOI: 10.1177/0896860820909702] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Velagapudi M, Sanley MJ, Ased S, Destache C, Malesker MA. Pharmacotherapy for nontuberculous mycobacterial pulmonary disease. Am J Health Syst Pharm 2021:zxab422. [PMID: 34788375 DOI: 10.1093/ajhp/zxab422] [Reference Citation Analysis]
12 DeStefano MS, Shoen CM, Cynamon MH. Therapy for Mycobacterium kansasii Infection: Beyond 2018. Front Microbiol 2018;9:2271. [PMID: 30319580 DOI: 10.3389/fmicb.2018.02271] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]